Cargando…

PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)

Detalles Bibliográficos
Autores principales:	Cooper, Nichola, Cuker, Adam, Michel, Marc, Wong, Raymond, Ghanima, Waleed, Zaja, Francesco, Barcellini, Wilma, Zhang, Fengkui, Lawniczek, Tomasz, Weill, Marine, Al-Samkari, Hanny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429351/ http://dx.doi.org/10.1097/01.HS9.0000977232.29155.a4

Ejemplares similares

PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
por: Zaja, Francesco, et al.
Publicado: (2023)

PB2552: VAYHIA: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL TO ASSESS THE EFFICACY AND SAFETY OF IANALUMAB VS PLACEBO IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA THAT FAILED ≥1 LINE OF TREATMENT
por: Barcellini, Wilma, et al.
Publicado: (2023)

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023)

Immune Thrombocytopenia (ITP): Current Limitations in Patient Management
por: Terrell, Deirdra R., et al.
Publicado: (2020)

Response to rituximab in children and adults with immune thrombocytopenia (ITP)
por: Harris, Emily M., et al.
Publicado: (2021)

Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia
por: Viana, Ricardo, et al.
Publicado: (2021)

Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States
por: Cuker, Adam, et al.
Publicado: (2023)

Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice
por: Song, Fei, et al.
Publicado: (2021)

P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0
por: Cooper, Nichola, et al.
Publicado: (2023)

Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life
por: Cooper, Nichola, et al.
Publicado: (2020)

Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
por: Tsykunova, Galina, et al.
Publicado: (2022)

PB2619: THE IMPACT OF ITP-DIRECTED TREATMENT ON FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
por: Diraimo, Jennifer, et al.
Publicado: (2023)

How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh)
por: Chakrabarti, Prantar, et al.
Publicado: (2022)

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
por: Lee, Eun-Ju, et al.
Publicado: (2022)

P1638: EARLY USE OF ELTROMBOPAG IN ADULT PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE CORTICOSTEROID THERAPY – AN AD HOC ANALYSIS OF THE TAPER TRIAL RESULTS
por: Ghanima, W., et al.
Publicado: (2022)

PB2620: NIGHTTIME SYMPTOMS ARE ASSOCIATED WITH FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
por: Diraimo, Jennifer, et al.
Publicado: (2023)

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM
por: Kolodny, Scott, et al.
Publicado: (2023)

Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment
por: Cooper, Nichola, et al.
Publicado: (2020)

PB2630: ASSESSEMENT OF THE MANAGEMENT OF ITP IN ADULTS IN AN INTERNAL MEDICINE DEPARTMENT IN ALGERIA
por: Imene, Semoud, et al.
Publicado: (2023)

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease
por: Cheloff, Abraham Z, et al.
Publicado: (2019)

PB2610: EPIDEMIOLOGY AND TREATMENT OF ITP: A SINGLE CENTRE, REAL-WORLD EXPERIENCE
por: Patel, Priya, et al.
Publicado: (2023)

Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern
por: Cuker, Adam, et al.
Publicado: (2021)

PB2298: THE RELATIONSHIP BETWEEN PLATELET SPECIFIC ANTIBODIES AND THE SEVERITY OF NEWLY DIAGNOSED PEDIATRIC ITP
por: Dong, S.
Publicado: (2022)

PB2632: DILLEMAS AND CHALLENGES IN ITP TREATMENT OF A PATIENT WITH THROMBOTIC AND HEMORRHAGIC EVENTS DEVELOPMENT
por: Smiljanic, Mihailo, et al.
Publicado: (2023)

COVID-19 vaccination and immune thrombocytopenia: Cause for vigilance, but not panic
por: Al-Samkari, Hanny
Publicado: (2023)

PB2311: LOW-DOSE PREDNISON AND ELTROMBOPAG COMBINATION AS FRONTLINE TREATMENT IN NEWLY DIAGNOSED ITP PATIENTS
por: Liu, S.-Y., et al.
Publicado: (2022)

Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
por: Zufferey, Anne, et al.
Publicado: (2017)

The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
por: Hughes, David
Publicado: (2022)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

PB2605: EFFICACY AND SAFETY OF MRNA COVID VACCINES IN ITP PATIENTS: A MONOCENTRIC REAL-LIFE STUDY
por: D’angelo, Simona, et al.
Publicado: (2023)

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
por: Al‐Samkari, Hanny, et al.
Publicado: (2022)

PB2300: COMPLEMENT ACTIVATION NEGATIVELY AFFECTS THE PLATELET RESPONSE TO THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE COHORT STUDY
por: Åkesson, A., et al.
Publicado: (2022)

PB2297: THE PREDICTIVE VALUE OF PLATELET SPECIFIC ANTIBODIES FOR THE FIRST-LINE TREATMENT EFFECT IN NEWLY DIAGNOSED PEDIATRIC ITP
por: Dong, S.
Publicado: (2022)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Immune Thrombocytopenia (ITP) Secondary to Subclinical Hashimoto’s Thyroiditis: Role of Levothyroxine in Improving the Clinical Outcome of ITP
por: Tahir, Hassan, et al.
Publicado: (2016)

Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP
por: Jawed, Muzamil, et al.
Publicado: (2021)

PB2615: HOW WILL COVID-19 RELATED SYMPTOMS AND PLATELET COUNTS CHANGE IN ITP PATIENTS AFTER COVID-19 INFECTION?
por: Chen, Xiaoli, et al.
Publicado: (2023)

PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)
por: Tsykunova, G., et al.
Publicado: (2022)

The role of romiplostim for pediatric patients with immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
por: Mcdonald, Vickie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4b24ctpckpho5agr40plpjsn2h